The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Breyanzi, a chimeric antigen receptor (CAR) T-cell therapy used to treat adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after standard treatments.

The approval was supported by research at Seattle Children’s, including the CAR T-cell product, patient product manufacturing for Juno Therapeutics’ TRANSCEND trial and data from the Pediatric Leukemia Adoptive Therapy (PLAT-02) clinical trial.

Read more: “Cancer Research at Seattle Children’s Contributes to FDA Approval of CAR T-Cell Immunotherapy Treatment for Adults with Relapsed or Refractory Large B-Cell Lymphoma,” in On the Pulse, Feb. 8, 2021.